Optimizing medical therapy of acromegaly: Beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide

Neuroendocrinology

Volumn 90, Issue 1, 2009, Pages 82-92

  Jallad, Raquel S ^a   Bronstein, Marcello D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acromegaly; Cabergoline; Long acting release octreotide; Octreotide; Pituitary tumors; Somatostatin; Somatostatin analogs

Indexed keywords

CABERGOLINE; GLUCOSE; GROWTH HORMONE; LONG ACTING DRUG; OCTREOTIDE; PROLACTIN; SOMATOMEDIN C;

ACROMEGALY; ADD ON THERAPY; ADULT; AGED; ARTICLE; BILE DUCT DISEASE; BILE DUCT STONE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROLITHIASIS; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; VISUAL IMPAIRMENT;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DRUG THERAPY, COMBINATION; ERGOLINES; FEMALE; GROWTH HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OCTREOTIDE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651108793     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218323     Document Type: Article

References (31)

1. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, Mahler C, Beckers A: Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83: 374-378. (Pubitemid 28496509)
2. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D: Longacting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005; 90: 4465-4473. (Pubitemid 41159328)
3. Minniti G, Jaffrain-Rea ML, Baldelli R, Ferretti E, Caracciolo B, Bultrini A, Gulino A, Tamburrano G: Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients. Clin Ter 1997; 148: 601-607. (Pubitemid 127737510)
4. Marzullo P, Ferone D, Di Somma C, Pivonello R, Filippella M, Lombardi G, Colao A: Efficacy of combined treatment with lanreotide and cabergoline in selected therapyresistant acromegalic patients. Pituitary 1999; 1: 115-120.
5. Cozzi R, Attanasio R, Lodrini S, Lasio G: Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004; 61: 209-215. (Pubitemid 39093116)
6. Selvarajah D, Webster J, Ross R, Newell- Price J: Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005; 152: 569-574. (Pubitemid 40575802)
7. Gatta B, Hau DH, Catargi B, Roger P, Tabarin A: Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients. Clin Endocrinol (Oxf) 2005; 63: 477-478. (Pubitemid 41442345)
8. Lundin P, Pedersen F: Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 1992; 16: 518-528.
9. Winer BJ, Brown DR, Michels KM: Statistical Principles in Experimental Design, ed 3. New York, McGraw-Hill, 1991.
10. Fisher LD, van Belle G: Biostatistics. New York, Wiley, 1993.
11. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL: Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 2002; 87: 3537-3542.
12. Freda PU, Post KD, Powell JS, Wardlaw SL: Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998; 83: 3808-3816.
13. Lamberts SW, Zweens M, Klijn JG, van Vroonhoven CC, Stefanko SZ, Del Pozo E: The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Clin Endocrinol (Oxf) 1986; 25: 201-212. (Pubitemid 16046359)
14. Gruszka A, Ren SG, Dong J, Culler MD, Melmed S: Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology 2007; 148: 6107-6114. (Pubitemid 350146153)
15. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, Scanarini M, Bondanelli M, Culler MD, degli Uberti EC: Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. J Mol Endocrinol 2005; 35: 333-341. (Pubitemid 41556180)
16. Li J, Stefaneanu L, Kovacs K, Horvath E, Smyth HS: Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas. Virchows Arch A Pathol Anat Histopathol 1993; 422: 193-201. (Pubitemid 23131500)
17. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G: Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997; 82: 518-523. (Pubitemid 27068622)
18. Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, Fortini P, Dubini A: Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf) 1988; 29: 467-476. (Pubitemid 18256772)
19. Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G: Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J Clin Invest 1997; 20: 537-546. (Pubitemid 28014506)
20. Jackson SNJ, Fowler J, Howlett TA: Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin Endocrinol (Oxf) 1997; 46: 745-749. (Pubitemid 27304460)
21. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC: Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288: 154-157. (Pubitemid 30203051)
22. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P: Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 2002; 87: 5545-5552. (Pubitemid 36034358)
23. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, Melmed S: Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003; 88: 5414-5421. (Pubitemid 37452747)
24. Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD: BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs. universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J Endocrinol Invest 2005; 28: 21-27.
25. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD: Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005; 153: 135-141. (Pubitemid 41030524)
26. Hussaini SH, Pereira SP, Veysey MJ, Kennedy C, Jenkins P, Murphy GM, Wass JA, Dowling RH: The roles of gallbladder emptying and intestinal transit in the pathogenesis of octreotide-induced gallbladder stones. Gut 1996; 38: 775-783. (Pubitemid 26167490)
27. Veysey MJ, Thomas LA, Mallet AI, Jenkins PJ, Besser GM, Wass JA, Murphy GM, Dowling RH: Prolonged large bowel transit increases serum deoxycholic acid - a risk factor for octreotide-induced gallbladder stones. Gut 1999; 44: 675-682.
28. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007; 356: 39-46. (Pubitemid 46041752)
29. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38. (Pubitemid 46041751)
30. Kars M, Pereira AM, Bax JJ, Romijn JA: Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required Eur J Endocrinol 2008; 159: 363-367.
31. Colao A, Spinelli L, Marzullo P, Pivonello R, Petretta M, Di Somma C, Vitale G, Bonaduce D, Lombardi G: High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. J Clin Endocrinol Metab 2003; 88: 3196-3201. (Pubitemid 36877494)